A phase 2 proof-of-concept trial in the orphan tauopathy disease progressive supranuclear palsy (PSP) in elderly patients

Trial Profile

A phase 2 proof-of-concept trial in the orphan tauopathy disease progressive supranuclear palsy (PSP) in elderly patients

Planning
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs ASN 120290 (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 13 Apr 2017 New trial record
    • 06 Apr 2017 This trial is expected to begin in 2018, according to an Asceneuron media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top